Recent News Releases
For investor-related news, see our ASX releases here.
Jun 6, 2022Seqirus Completes $156 Million Expansion to Holly Springs Manufacturing Facility, Optimizing Global Manufacturing Capabilities for Seasonal and Pandemic Influenza Vaccines
Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), today announced the completion of an expansion to the company’s manufacturing facility in Holly Springs, N.C., supporting the formulation and fill-finish of its cell-based influenza vaccines in pre-filled syringes for global communities.
May 24, 2022FDA Accepts CSL Behring's Biologics License Application for Etranacogene Dezaparvovec for Priority Review
-- If approved, etranacogene dezaparvovec would be the first gene therapy option for people living with hemophilia B -- This milestone underscores CSL Behring's promise to develop and deliver a...
May 12, 2022
St. Gallen, Switzerland, 12 May 2022 – CSL Limited (ASX: CSL; USOTC:CSLLY) yesterday announced an update regarding the Vifor Pharma AG acquisition. CSL has previously advised that it expected to...
May 11, 2022
Statement attributable to Greg Boss, Executive Vice President - Legal, and CSL Limited Group General Counsel. 11 May 2022 We are encouraged by the United States Court of Appeals for the District...
Apr 28, 2022Kapruvia® approved by European Commission for the treatment of moderate-to-severe pruritus in hemodialysis patients
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR First approved therapy in Europe for the treatment of chronic kidney disease (CKD)-associated pruritus in hemodialysis patients First launches in Europe...
Apr 28, 2022CSL Behring Donates 500 Million International Units of Coagulation Factor Replacement Therapy to the World Federation of Hemophilia Humanitarian Aid Program to Help Those Living with Bleeding Disorders
The 500 million international units (IUs) will include product specifically manufactured for donation allowing for a longer shelf life and enabling more people around the world to access...
Apr 26, 2022
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Shareholders agreed to the Board of Directors’ recommendations for all proposed resolutions Dividend of CHF 2.00 approved All Board members re-elected...
- Apr 26, 2022
CSL ranked fourth on the Health Industry list, from a total of more than 750 organisations nominated in all sectors across Australia and New Zealand. MELBOURNE, 27, April: Today, CSL is honoured...
Apr 4, 2022DIAMOND trial: Veltassa® enables patients to achieve long-term potassium control and optimized RAASi therapy
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Full data set supports long-term use of Veltassa® (patiromer) to control potassium buildup (hyperkalemia) in heart failure patients while on...
Mar 28, 2022
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Melbourne, Australia and St. Gallen, Switzerland, 28 March 2022 – CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of global biotechnology...